Cayman Islands Directors Registration and Licensing Law, 2014

EQS-News: Marcel Lux III SARL: Notification of Publication of Offer Document

Retrieved on: 
Thursday, August 24, 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN OR INTO ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

Key Points: 
  • NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN OR INTO ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
  • This publication is neither an offer to purchase nor a solicitation of an offer to sell shares in SUSE or any other securities.
  • The Offer itself as well as its definite terms and conditions and further provisions concerning the Offer are published in the Offer Document.
  • Investors and SUSE Shareholders are strongly advised to thoroughly read the entire Offer Document and all other relevant documents regarding the Offer when they become available, as they will contain important information.

ANI Pharmaceuticals Announces Proposed Public Offering of Common Stock

Retrieved on: 
Thursday, May 11, 2023

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI”) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Key Points: 
  • ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI”) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
  • All of the shares to be sold in the offering will be offered by ANI.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • In addition, ANI intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of its common stock offered in the public offering.

Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report

Retrieved on: 
Friday, April 28, 2023

Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases announced that on 27 April 2023 SIX Exchange Regulation ("SER") approved a deadline extension until the end of May 2023 for the publication of the Kinarus 2022 annual financial report.

Key Points: 
  • Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases announced that on 27 April 2023 SIX Exchange Regulation ("SER") approved a deadline extension until the end of May 2023 for the publication of the Kinarus 2022 annual financial report.
  • In addition, in line with the decision of SER, Kinarus will publish certain unaudited key financial figures for the financial year 2022 by 5 May 2023.
  • In accordance with the regulations of SIX Swiss Exchange, Kinarus applied to SER for an extension of the deadline for publication of its 2022 annual financial report.
  • Kinarus is currently finalizing the financial statements on a consolidated basis, including its subsidiaries, as required for the annual financial reporting requirements.

Futu Ranks #2 on Fortune's 100 Fastest-Growing Companies List For 2022

Retrieved on: 
Friday, November 18, 2022

PALO ALTO, Calif., Nov. 18, 2022 /PRNewswire/ --Moomoo's parent company, Futu Holdings Limited (Nasdaq: FUTU), a leading tech-driven digitalized brokerage and wealth management platform, is pleased to announce that it is ranked 2nd on Fortune's "100 Fastest-Growing Companies list 2022.

Key Points: 
  • PALO ALTO, Calif., Nov. 18, 2022 /PRNewswire/ --Moomoo's parent company, Futu Holdings Limited (Nasdaq: FUTU), a leading tech-driven digitalized brokerage and wealth management platform, is pleased to announce that it is ranked 2nd on Fortune's "100 Fastest-Growing Companies list 2022.
  • This ranking is based on its outstanding operational performance and Futu is the top-ranked financial company for 2022.
  • Fortune's"100 Fastest-Growing Companies List", now in its 37th year, ranks companies based on growth in revenue, profits, and stock returns, over a three-year period ending June 30, 2022.
  • Futu Holdings Limited ("Futu") (Nasdaq: FUTU) is an advanced technology company transforming the investing experience by offering a fully digitized brokerage and wealth management platform.

Vicarious Surgical Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022

Vicarious Surgical Inc. (Vicarious Surgical or the Company) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended June 30, 2022.

Key Points: 
  • Vicarious Surgical Inc. (Vicarious Surgical or the Company) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended June 30, 2022.
  • R&D expenses for the second quarter of 2022 were $10.1 million, compared to $4.0 million in the second quarter of 2021.
  • General and administrative expenses for the second quarter of 2022 were $7.8 million, compared to $2.3 million in the second quarter of 2021.
  • ET on Monday, August 8, 2022, to discuss its second quarter 2022 financial results.

Arrival Annual General Meeting and Extraordinary General Meeting Approved All Proposals Today

Retrieved on: 
Friday, June 3, 2022

The AGM approved, among others, the annual accounts and consolidated annual accounts of Arrival for the financial year ended 31 December 2021 and re-elected Frank Peter Cuneo and Yun Seong Hwang as class A directors.

Key Points: 
  • The AGM approved, among others, the annual accounts and consolidated annual accounts of Arrival for the financial year ended 31 December 2021 and re-elected Frank Peter Cuneo and Yun Seong Hwang as class A directors.
  • Our in-house technologies enable our unique new method of design and production using rapidly-scalable, local Microfactories around the world.
  • This vertically integrated business model is how we can have the radical impact our world needs today.
  • Arrival (NASDAQ: ARVL) is a joint stock company governed by Luxembourg law.

Ahren Acquisition Corp. Announces the Appointment of Jonathan Roney to the Board of Directors

Retrieved on: 
Thursday, April 7, 2022

Mr. Roney acts as a professional independent director for hedge funds, private equity funds and investment management companies.

Key Points: 
  • Mr. Roney acts as a professional independent director for hedge funds, private equity funds and investment management companies.
  • Mr. Roney is a Professional Director registered pursuant to the Cayman Islands Directors Registration and Licensing Act 2014.
  • Ahren Acquisition Corp. is a blank check company whose business purpose is to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
  • The Companys sponsor is AACS LP, which is an affiliate of Ahren LP (Ahren).

Hyperfine Receives FDA Clearance for Deep Learning Portable MRI, Defining the Future of Life-Saving Diagnostics

Retrieved on: 
Monday, November 29, 2021

The result is Swoop, an easy-to-use, portable, and affordable system costing less than the annual service contract of many conventional MRI systems.

Key Points: 
  • The result is Swoop, an easy-to-use, portable, and affordable system costing less than the annual service contract of many conventional MRI systems.
  • With the launch of its deep learning-based advanced image reconstruction technology, Swoopcan deliver crisp, clear T1, T2, and FLAIR images.
  • In January, Hyperfine received FDA clearance for its advanced artificial intelligence (AI) application.
  • Hyperfine, Inc. is the groundbreaking medical device company that created Swoop, the world's first FDA-cleared portable MRI system.

Hyperfine Appoints Scott White as Chief Commercial Officer

Retrieved on: 
Thursday, October 28, 2021

GUILFORD, Conn., Oct. 28, 2021 /PRNewswire/ --Hyperfine, Inc., creator of the first FDA-cleared portable magnetic resonance imaging (MRI) device, Swoop, today announced the appointment of Scott White as chief commercial officer.

Key Points: 
  • GUILFORD, Conn., Oct. 28, 2021 /PRNewswire/ --Hyperfine, Inc., creator of the first FDA-cleared portable magnetic resonance imaging (MRI) device, Swoop, today announced the appointment of Scott White as chief commercial officer.
  • "Scott has a track record of delivering commercial revenue, executing organizational growth strategies, and building key relationships," said Hyperfine President and Chief Executive Officer Dave Scott.
  • "The team at Hyperfine is committed to effecting permanent change to the hospital environment to better serve medical professionals and patients around the world," said White.
  • White joins the Hyperfine team following recent appointments of Chief Financial Officer Alok Gupta, President and Chief Executive Officer Dave Scott, and Executive Chairman Scott Huennekens.